Result of General Meeting
18 February 2021
At the General Meeting held earlier tod ay both the resolutions were duly approved by shareholders:
Resolution (*indicates special resolution)
Votes for (1)
% of shares voted (2)
Votes against (3)
% of shares voted
Resolution 1: to authorise the Directors to allot shares in the Company
Resolution 2*: t o disapply pre-emption rights
( 1) Any proxy appointments which gave discretion to the Chairman have been included in the "for" total.
(2) As a percentage of the aggregate of votes "for" plus votes "against".
(3) An abstention is not counted towards the votes cast "for" or "against" a resolution.
Allotment of Shares
At a board meeting following the General Meeting, the Company has allotted 207,424,361 new ordinary shares of 0.1p each ("Ordinary Shares") comprising 126,628,576 Placing Shares, 39,085,710 Firm Subscription Shares, 28,571,428 Conditional Placing Shares and 13,138,647 Conversion Shares.
Application has been made for the admission to trading on AIM ("First Admission") of the Placing Shares, the Firm Subscription Shares and the Conversion Shares (amounting to 178,852,933 new Ordinary Shares), and First Admission is expected at 8.00 a.m. on or around 19 February 2021.
Application has been made for the admission to trading on AIM ("Second Admission") of the Conditional Subscription Shares (amounting to 28,571,428 new Ordinary Shares), and Second Admission is expected at 8.00 a.m. on or around 22 February 2021.
Total Voting Rights
Following First Admission, the Company's issued share capital will comprise 696,674,608 ordinary shares with one voting right each. As the Company does not hold any shares in Treasury, the total number of voting rights in the Company is also 696,674,608 and this figure of ordinary shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Following Second Admission, the Company's issued share capital will comprise 725,246,036 ordinary shares with one voting right each, and total number of voting rights in the Company will be 725,246,036.
Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement released on 29 January 2021 unless the context requires otherwise.
For further information please visit http://www.myhealthcheckedplc.com/ or contact:
Penny McCormick , Chief Executive Officer
via Walbrook PR
Maddy Kennedy, Chief Financial Officer
SPARK Advisory Partners Limited (NOMAD)
Tel: +44 (0)20 3368 3550
Oberon Investments (Broker)
Tel: +44 (0)203 179 5344
Walbrook PR Ltd (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or [email protected]
Mob: +44(0)7980 541 893